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Background 
The electronic Persistent Pain Outcomes Collaboration (ePPOC) is a program 
which aims to improve services and outcomes for people experiencing 
chronic pain. It involves the collection of a standard set of data items and 
assessment tools by specialist pain services throughout Australia and New 
Zealand, allowing measurement of patient outcomes as a result of treatment. 
The information collected is also used to develop an Australasian 
benchmarking system for the pain sector, facilitating better outcomes and 
best practice interventions for people experiencing chronic pain.  
ePPOC is a sub-centre of the Australian Health Services Research Institute at 
the University of Wollongong. Further information about ePPOC is available 
at https://ahsri.uow.edu.au/eppoc. Other enquiries can be directed to 
eppoc@uow.edu.au or (+61) 2 4221 5058. 
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The ePPOC report suite  
ePPOC produces a report suite for your service every six months which includes the following components: 
 a Dashboard: a one-page infographic presenting information about your patients, the treatments you 
provided and the outcomes your patients achieved.  
 an Executive Summary: a summary of your service data, presented alongside data from all services 
for comparative purposes, and including benchmark and indicator information. 
 this Report: a detailed report presenting data and information on your service’s patient profile, 
episodes of care and patient outcomes, alongside that for all services. 
The dashboard and executive summary are stand-alone documents available from the ePPOC On-line Portal 
(EOP). 
 
This report 
Participating pain management services 
Seventy-three pain management services provided data for this report. These services are located across 
Australia and New Zealand (Figure 1) and listed in Appendix D. 
Figure 1 – Location of participating pain services 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report period and scope 
This report provides information about pain service activity that occurred during the period July 2019 to June 
2020. Sections of the report describe: 
 The profile of patients who began their engagement with the pain service during this period (i.e. 
completed a referral questionnaire) 
 The episodes of care that began, services that were provided and the episodes that ended during this 
period 
 Patient outcomes at the end of the episode for the patients who completed the relevant patient-reported 
outcome questionnaire during the period 
 Post-episode patient outcomes for the patients who completed the relevant patient-reported outcome 
questionnaire during the period 
This information and the report section in which it is presented is depicted in Figure 2. 
Note that the same individuals may not be represented in each section of the report.   
4 
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Figure 2 – The information described in each (colour coded) section of the report    
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Patient profile 
This section provides socio-demographic and clinical information about the people who completed an ePPOC 
Referral Questionnaire during the period 1 July 2019 to 30 June 2020.  
Socio-demographic details 
 
Table 1 – Sex 
Enterprise One All services 
Number % Number % 
Male 150 35.5 8629 42.4 
Female 268 63.4 11658 57.3 
Not stated/described 5 1.2 68 0.3 
Total 423 100.0 20355 100.0 
 
Table 2 – Age (years) 
Enterprise One All services 
Average Median Average Median 
All patients 52.5 53.0 50.2 50.0 
- Male 49.8 50.0 49.8 50.0 
- Female 53.7 54.0 50.5 51.0 
- Not stated/described 63.8 63.0 47.2 49.0 
 
 
Figure 3 – Age group by sex 
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Table 3 – Indigenous status 
Enterprise One All services 
Number % Number % 
Aboriginal but not Torres Strait Islander 15 4.0 613 4.3 
Torres Strait Islander but not Aboriginal 0 0.0 20 0.1 
Both Aboriginal & Torres Strait Islander 0 0.0 9 0.1 
Neither Aboriginal nor Torres Strait Islander 363 96.0 13771 95.5 
Total 378 100.0 14413 100.0 
 
Table 4 – Country of birth 
Enterprise One All services 
Number % Number % 
Australia 293 70.8 10607 52.8 
New Zealand 35 8.5 4463 22.2 
Other 86 20.8 5009 24.9 
Total 414 100.0 20079 100.0 
 
 
Figure 4 – Socioeconomic area disadvantage based on patient postcode 
 
 
 
 
 
 
 
 
This chart shows patient residential area grouped into five disadvantage quintiles (from least 
to most disadvantage) such that across the Australian and New Zealand populations, 20% of 
people live in each disadvantage quintile. It is important to note that the level of 
disadvantage relates to the area the patient lives in rather than the patient.  
The chart compares the proportion of your patients who live in each disadvantage quintile to 
the population of all people seeking pain management in Australasia (All services). 
The red line shows the expected distribution of disadvantage – Australasia (expected 
percentage). 
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Table 5 – Referral source 
Enterprise One All services 
Number % Number % 
General practitioner/nurse practitioner  261 61.7 10929 53.7 
Specialist practitioner 19 4.5 3257 16.0 
Other pain management service 0 0.0 917 4.5 
Public hospital 129 30.5 1760 8.6 
Private hospital 0 0.0 31 0.2 
Rehabilitation provider/private insurer 12 2.8 1747 8.6 
Other 2 0.5 1714 8.4 
Total 423 100.0 20355 100.0 
 
 
Table 6 – Did the patient require an 
interpreter? 
Enterprise One All services 
Number % Number % 
Yes 5 1.2 762 3.8 
No 412 98.8 19258 96.2 
Total 417 100.0 20020 100.0 
 
 
Table 7 – Was the patient hearing or 
sight impaired? 
Enterprise One All services 
Number % Number % 
Yes 78 18.9 2811 14.1 
No 335 81.1 17076 85.9 
Total 413 100.0 19887 100.0 
 
 
Table 8 – Was assistance required 
with written or spoken 
communication? 
Enterprise One All services 
Number % Number % 
Yes 24 5.9 1499 7.7 
No 381 94.1 17890 92.3 
Total 405 100.0 19389 100.0 
 
 
Table 9 – Did the episode of care 
involve a compensation case? 
Enterprise One All services 
Number % Number % 
Yes 34 9.0 2426 16.7 
No 343 91.0 12100 83.3 
Total 377 100.0 14526 100.0 
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Table 10 – Is the patient a previous or 
serving member of the Australian 
Defence Force? 
Enterprise One All services 
Number % Number % 
Yes 11 2.9 589 4.1 
No 364 97.1 13843 95.9 
Total  375 100.0 14432 100.0 
 
 
Table 11 – Is the patient a client of 
the Department of Veteran's Affairs? 
Enterprise One All services 
Number % Number % 
Yes 1 0.3 348 2.4 
No 376 99.7 14047 97.6 
Total  377 100.0 14395 100.0 
 
 
Table 12 – Is the episode of care for 
the management of cancer pain? 
Enterprise One All services 
Number % Number % 
Yes 0 0.0 168 0.8 
No 423 100.0 20187 99.2 
Total 423 100.0 20355 100.0 
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Clinical characteristics  
Health and comorbidities 
Figure 5 – Distribution of Body Mass Index  
  
 
 
Table 13 – Pain-related health service use in the 
past 3 months (average) 
Enterprise One All services 
General practitioner 5.5 4.6 
Medical specialist 1.0 1.3 
Other health professionals 3.7 4.5 
Emergency department presentations 0.6 0.5 
Hospital admissions 0.3 0.2 
Diagnostic tests 1.4 1.4 
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* Comorbidities are patient reported 
 
 
Pain Characteristics 
Table 15 – How the main pain 
began (the precipitating event) 
Enterprise One All services 
Number % Number % 
Injury at home  42 10.2 2067 10.4 
Injury at work/school 74 18.0 4791 24.2 
Injury in another setting 42 10.2 1806 9.1 
After surgery 35 8.5 1623 8.2 
Motor vehicle crash 34 8.3 1954 9.9 
Related to cancer 1 0.2 259 1.3 
Related to another illness 65 15.8 2474 12.5 
No obvious cause 62 15.1 2821 14.2 
Other 56 13.6 2035 10.3 
Total 411 100.0 19830 100.0 
 
  
Table 14 – Comorbid conditions* 
Enterprise One All services 
Number % Number % 
Mental health condition 236 55.8 8702 42.8 
- PTSD 59 13.9 2296 11.3 
- Anxiety 159 37.6 6037 29.7 
- Depression 173 40.9 6733 33.1 
Arthritis 205 48.5 7189 35.3 
Muscle, bone and joint problems  
(other than arthritis) 
184 43.5 6890 33.8 
Heart and circulation problems  125 29.6 4603 22.6 
- High Blood Pressure 66 15.6 2649 13.0 
- High Cholesterol 43 10.2 1537 7.6 
Diabetes 55 13.0 2273 11.2 
Digestive problems 153 36.2 5443 26.7 
Respiratory problems  132 31.2 4909 24.1 
Neurological problems  56 13.2 1597 7.8 
Cancer 20 4.7 862 4.2 
Liver, kidney and pancreas problems  45 10.6 1493 7.3 
Thyroid problems  44 10.4 1709 8.4 
Other medical conditions 103 24.3 4450 21.9 
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Table 16 – Pain duration – how 
long the main pain has been 
present 
Enterprise One All services 
Number % Number % 
Less than 3 months 3 0.7 592 3.0 
3 to 12 months 46 11.1 3659 18.6 
12 months to 2 years 54 13.0 3106 15.8 
2 to 5 years 91 22.0 4218 21.5 
More than 5 years 220 53.1 8055 41.0 
Total 414 100.0 19630 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 18 – Number of pain areas 
Enterprise One All services 
Number % Number % 
1 49 11.8 2485 12.7 
2-3 118 28.4 6511 33.2 
4-6 159 38.3 7221 36.9 
7-9 68 16.4 2827 14.4 
10+ 21 5.1 546 2.8 
Total 415 100.0 19590 100.0 
 
  
Table 17 – Main pain area 
Enterprise One All services 
Number % Number % 
Head 12 3.9 767 4.5 
Neck 20 6.4 1273 7.5 
Chest 3 1.0 307 1.8 
Back  154 49.5 7229 42.6 
Leg 13 4.2 1135 6.7 
Arm/shoulder 33 10.6 1914 11.3 
Abdomen 11 3.5 675 4.0 
Hands 9 2.9 436 2.6 
Feet 15 4.8 762 4.5 
Pelvic and/or genital 10 3.2 359 2.1 
Buttocks 0 0.0 0 0.0 
Knee 13 4.2 902 5.3 
Hip 18 5.8 1219 7.2 
Total 311 100.0 16978 100.0 
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Symptom severity  
Table 19 – Assessment tool scores  
Enterprise One All services 
Mean (std. deviation) Mean (std. deviation) 
Pain severity 6.0 (1.8) 6.2 (1.8) 
Pain interference 6.5 (2.1) 6.9 (2.0) 
Depression 17.5 (11.9) 18.6 (12.5) 
Anxiety 13.0 (10.0) 12.9 (10.3) 
Stress 19.1 (11.2) 19.9 (11.1) 
Pain catastrophising  25.5 (13.4) 27.6 (13.8) 
Pain self-efficacy  25.0 (12.7) 21.6 (12.9) 
Note: Pain severity is an average of the four Brief Pain Inventory severity items. For pain self-efficacy, higher scores reflect 
greater confidence in ability to perform activities despite the pain. 
 
The proportion of patients who reported moderate or worse symptom severity on each of the domains 
measured in the assessment tools is shown in Figure 61.   
 
Figure 6 – Patients with moderate or worse symptom severity (%)  
 
 
  
                                                     
1 Note that the ePPOC benchmarks (shown in later sections of this report) include only those patients who 
report moderate or worse severity on the clinical domain.  
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Medication use 
The following information refers to the patients who reported medication information at referral, and for 
whom staff recorded details of medication use in epiCentre. Patient numbers at your service and at all services 
are shown in Figure 7. This figure also shows the major drug groups used by patients for whom medication 
use has been reported.  
 
Figure 7 – Medication use by type of drug  
 
 
The proportion of patients who were using opioid medications on more than 2 days per week is shown in 
Table 20. The average and median oral morphine equivalent daily dose (oMEDD) is shown in Table 21 for the 
patients who were taking opioid medications, and for whom an oMEDD was reported.  
 
Table 20 – Frequency of use of opioid 
medication  
Enterprise One All services 
Percent of people using opioid medications 
>2 days per week  
51.7 53.8 
 
Table 21 – oMEDD at referral  
Enterprise One 
n = 160 
All services 
n = 8365 
Average (mg) 48.4 55.5 
Median (mg) 30.0 31.2 
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Employment status and productivity 
Information about work status is shown in Table 22.  For patients who reported that they were working full- or 
part-time, additional information was collected (Table 23). This information allowed calculation of: 
 The percent of time missed from work due to pain (absenteeism) 
 The percent of work impairment while working due to pain (lost productivity) 
 Overall work impairment due to pain, reported as a percentage. Overall work impairment takes into 
account both absenteeism and lost productivity. 
 
Table 22 – Employment status  
Enterprise One All services 
n (%) n (%) 
Working full-time 47 (12.2) 3254 (17.7) 
Working part-time 46 (11.9) 2391 (13.0) 
Unable to work due to pain   133 (34.5) 6827 (37.1) 
Unable to work due to a condition other than pain  64 (16.6) 2475 (13.4) 
Not working by choice 85 (22.1) 3085 (16.8) 
Seeking employment 10 (2.6) 372 (2.0) 
Total 385 (100.0) 18404 (100.0) 
 
Table 23 – Work productivity and impairment (%) for 
people working full- or part-time 
Enterprise One All services 
Work time missed due to pain  16.9% 21.4% 
Pain affected work productivity  53.1% 57.7% 
Overall work impairment 58.5% 64.2% 
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The episode of care 
An episode of care is a continuous period of care for a person in one pain management service. An episode 
begins with the first clinical contact with the patient and ends when active treatment at the pain service is 
completed. This section of the report provides a description of waiting time, how episodes started and ended, 
and the services provided to patients.  
Waiting time 
Wait time is measured from: 
 referral to the start of the episode (i.e. the date the referral is received at the pain management service to 
the first clinical contact); and  
 referral to the start of the first treatment pathway (i.e. the date the referral is received at the pain 
management service to the date that active treatment begins, e.g. a group pain program, procedure, 
series of individual appointments) 
Table 24 – Waiting time Enterprise One All services 
Time from referral to the start of the episode    
     – average (days) 114.1 103.3 
     – median (days) 72.0 61.0 
Time from referral to the start of the first treatment pathway    
     – average (days) 116.3 107.1 
     – median (days) 66.0 55.0 
 
Figure 8 – Time from referral to episode start, shown as a percent of people in each time category 
 
 
Figure 9 and Figure 10 show the position of your service compared to other pain management services based 
on median wait time from referral to episode start, and referral to treatment pathway start. 
Figure 9 – Median number of days from referral  
to episode start 
Figure 10 – Median number of days from referral to  
first treatment pathway 
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Figure 11 and Figure 12 compare the proportion of patients at your service who were seen within three 
months and eight weeks, compared to all other services. The time series charts show change in these 
measures over the past five years. 
 
Figure 11 – Wait time (patients seen within 3 months) – Indicator 1 
  
 
 
Figure 12 – Wait time (patients seen within 8 weeks) – Indicator 2 
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Episode start 
During the period 1 July 2019 to 30 June 2020, 364 patients started an episode of care at your service.  
Table 25 – How the episode started 
Enterprise One All services 
Number % Number % 
Multidisciplinary assessment/treatment 65 17.9 6855 38.6 
Single clinician assessment/treatment 13 3.6 6633 37.4 
Education/orientation Program 286 78.6 4257 24.0 
Total 364 100.0 17745 100.0 
 
Services provided 
 
Table 26 – Service events provided at your service 
(total hours)  
Total hours Via telehealth2 
Individual appointment with ….   
– medical practitioner 64.5 0.0 
– physiotherapist 156.0 0.0 
– psychologist 71.5 0.0 
– occupational therapist 144.5 0.0 
– nurse 0.0 0.0 
– one or more clinicians 4.0 0.0 
–  other 0.0 0.0 
Multidisciplinary team assessment 113.8 42.3 
Multidisciplinary panel discussion 0.0 0.0 
Telephone/email consultation with patient/carer 2.3 1.0 
Telephone/email consultation with another clinician 0.0 0.0 
Pain management program – group 322.0 0.0 
Pain management program – individual 0.0 0.0 
Procedural intervention  
– implant (drug delivery/refill) 0.0 0.0 
– implant (neurostimulation/trial) 0.0 0.0 
– non-implant (for therapeutic intent) 0.0 0.0 
– cancer block 0.0 0.0 
– other (for diagnostic intent) 0.0 0.0 
Education/orientation program 108.0 13.5 
Other 1.0 0.0 
Total 987.5 56.8 
 
 
                                                     
2 Telehealth hours are a subset of total hours 
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Figure 13 – Service events, percentage by type 
 
Treatment pathways 
85 treatment pathways were started during the period 1 July 2019 to 30 June 2020. The number and 
proportion of each type are shown in Table 27. 
Table 27 – Treatment pathways  
Enterprise One All services 
Number % Number % 
Group pain program 16 18.8 2443 22.2 
Individual appointments 16 18.8 7433 67.6 
Concurrent (group and individual) 53 62.4 997 9.1 
Other 0 0.0 116 1.1 
Total 85 100.0 10989 100.0 
 
Table 28 – Average pathway length 
(days) by pathway type  
Enterprise One All services 
Group pain program 45.4 62.1 
Individual appointments 213.1 196.4 
Concurrent (group and individual) 319.3 185.3 
Other - 58.7 
Episode end 
During this period, 214 patients completed an episode of care at your service. 
Table 29 – How the episode ended 
Enterprise One All services 
Number % Number % 
Treatment complete – self 
management/referral to primary care 
118 55.1 7528 58.5 
Referral to another pain service 3 1.4 293 2.3 
Patient discontinued by choice 42 19.6 2121 16.5 
Died 2 0.9 54 0.4 
Active treatment complete – ongoing review 9 4.2 1779 13.8 
Lost to follow-up/not for follow-up 40 18.7 1096 8.5 
Total  214 100 12873 100 
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Table 30 – Length of the episode Enterprise One All services 
Average 308.0 265.8 
Median 240.0 175.0 
 
Table 31 – Length of the episode - 
distribution 
Enterprise One All services 
Number % Number % 
Less than 1 month 8 3.7 1230 9.6 
1 to 2 months 5 2.3 845 6.6 
3 to 6 months 63 29.4 4597 35.7 
7 to 9 months 33 15.4 1537 11.9 
10 to 12 months 34 15.9 1638 12.7 
More than 12 months 71 33.2 3026 23.5 
Total  214 100.0 12873 100.0 
 
Table 32 shows the average service events (total and by type) delivered for an episode of care.  
 
Table 32 – Service duration (average hours) 
Enterprise One All services 
Total Telehealth Total Telehealth 
Individual appointment with … 
  – medical practitioner 
1.3 0.0 1.1 0.0 
  – physiotherapist 6.5 0.0 4.0 0.0 
  – psychologist 2.5 0.0 1.4 0.0 
  – occupational therapist 3.4 0.0 0.7 0.0 
  – nurse 0.0 0.0 0.2 0.0 
  – one or more clinicians 0.0 0.0 0.1 0.0 
  – other 0.1 0.0 0.2 0.0 
Multidisciplinary team assessment 0.2 0.0 0.7 0.0 
Multidisciplinary panel discussion 0.0 0.0 0.1 0.0 
Telephone/email consultation with patient/carer 0.0 0.0 0.2 0.0 
Telephone/email consultation with another clinician 0.0 0.0 0.0 0.0 
Pain management program – group 6.5 0.1 11.7 0.1 
Pain management program – individual 0.0 0.0 0.3 0.0 
Procedural intervention  
  – implant (drug delivery/refill) 
0.0 0.0 0.0 0.0 
  – implant (neurostimulation/trial) 0.0 0.0 0.0 0.0 
  – non-implant (for therapeutic intent) 0.0 0.0 0.1 0.0 
  – cancer block 0.0 0.0 0.0 0.0 
  – other (for non-therapeutic intent) 0.0 0.0 0.0 0.0 
Education/orientation program 0.7 0.0 0.9 0.0 
Other 0.0 0.0 0.1 0.0 
Total 21.2 0.1 21.9 0.2 
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Patient outcomes at the end of the episode 
During the period 1 July 2019 to 30 June 2020, 89 of your patients completed an ePPOC questionnaire at the 
end of their episode of care. This section shows the outcomes for these patients, reported as change from 
referral to the end of the episode. 
 
Global rating of change 
The global rating of change (GRC) captures the person’s perception about how their condition has changed 
(both overall and in respect to physical functioning) compared to before receiving treatment at the pain 
service.  
 
Figure 14 – Global rating of change at episode end 
  
68.5% of your patients reported making at least some overall improvement3, and 62.9% reported an 
improvement in their physical abilities (74% and 70.6% at all services – see Figure 14).  
  
                                                     
3 The sum of responses 1, 2 and 3 
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Pain 
Pain severity 
The severity of pain is measured using the Brief Pain Inventory (BPI). Average scores on the BPI at referral and 
at episode end are shown in Table 33. The proportion of people in each severity category at referral and 
episode end is shown in Figure 15.  
 
Table 33 – Pain at referral and episode 
end 
Enterprise One 
n = 78 
All services 
n = 4824 
Referral  Episode end Referral  Episode end 
Pain severity 5.7 5.0 5.8 4.7 
- Worst pain 7.5 6.7 7.7 6.5 
- Least pain 3.9 3.4 4.0 3.2 
- Average pain 5.6 5.0 5.8 4.7 
- Pain now 5.6 4.7 5.7 4.6 
 
Figure 15 – Pain severity category at referral and episode end 
 
 
Figure 16 – Average pain benchmark results and time series 
  
The benchmark chart above (see Appendix C for tips on interpretation) 
shows the percentage of patients reporting moderate or worse pain at 
referral who make a clinically significant improvement at episode end. 
Enterprise One: n = 14 (23.3%) 
All services: n = 1244 (32.7%)  
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Pain interference 
The interference of pain in activities is measured using the Brief Pain Inventory (BPI). Average scores on the BPI 
at referral and episode end are shown in Table 34. The proportion of people in each severity category at 
referral and episode end is shown in Figure 17.  
 
Table 34 – Pain interference at 
referral and episode end 
Enterprise One 
n = 80 
All services 
n = 4963 
Referral  Episode end Referral  Episode end 
Pain Interference 6.4 5.2 6.7 4.9 
 
Figure 17 – Pain interference category at referral and episode end 
 
 
Figure 18 – Pain interference benchmark results and time series 
  
The benchmark chart above shows the percentage of patients reporting 
moderate or worse pain interference at referral who make a clinically 
significant improvement at episode end. 
Enterprise One: n =  36 (53.7%) 
All services: n =  2671 (62.6%) 
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Pain frequency 
Table 35 and Figure 19 report the percent of patients reporting the frequency at which pain is experienced, at 
referral and at the end of the episode. 
 
Table 35 – Pain frequency at referral 
and episode end (%) 
Enterprise One 
n = 80 
All services 
n = 4815 
Referral  
Episode 
end 
Referral  
Episode 
end 
Always present (same intensity) 11.3 11.3 9.8 6.6 
Always present (varying intensity) 72.5 62.5 72.2 55.1 
Often present 11.3 15.0 13.0 16.5 
Occasionally present 0.0 10.0 3.7 12.8 
Rarely present 5.0 1.3 1.3 8.0 
Pain no longer present 0.0 0.0 0.0 1.1 
Total 100.0 100.0 100.0 100.0 
 
 
Figure 19 – Pain frequency – distribution at referral and episode end 
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Depression 
Depression is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average depression scores 
at referral and episode end are shown in Table 36. The proportion of people in each severity category at 
referral and episode end is shown in Figure 20.  
 
Table 36 – Depression at 
referral and episode end 
Enterprise One 
n = 76 
All services 
n = 4893 
Referral score Episode end Referral score Episode end 
Depression 18.4 13.8 17.3 12.4 
 
Figure 20 – Depression severity category at referral and episode end  
 
 
Figure 21 – Depression benchmark results and time series 
  
The benchmark chart above shows the percentage of patients 
reporting moderate or worse depression at referral who make a 
clinically significant improvement at episode end. 
Enterprise One: n = 22 (44.9%) 
All services: n = 1628 (58.1%) 
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Anxiety  
Anxiety is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average anxiety scores at 
referral and episode end are shown in Table 37. The proportion of people in each severity category at referral 
and episode end is shown in Figure 22. 
 
Table 37 – Anxiety at 
referral and episode end 
Enterprise One 
n = 77 
All services 
n = 4885 
Referral score Episode end Referral score Episode end 
Anxiety 12.8 10.4 11.7 9.6 
 
Figure 22 – Anxiety severity category at referral and episode end  
 
 
Figure 23 – Anxiety benchmark results and time series  
   
The benchmark chart above shows the percentage of patients 
reporting moderate or worse anxiety at referral who make a clinically 
significant improvement at episode end. 
Enterprise One: n = 23 (46.0%) 
All services: n = 1125 (45.3%) 
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Stress 
Stress is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average stress scores at referral 
and episode end are shown in Table 38. The proportion of people in each severity category at referral and 
episode end is shown in Figure 24. 
 
Table 38 – Stress at 
referral and episode end 
Enterprise One 
n = 76 
All services 
n = 4872 
Referral score Episode end Referral score Episode end 
Stress 19.7 16.1 19.4 15.2 
 
Figure 24 – Stress severity category at referral and episode end  
 
 
Figure 25 – Stress benchmark results and time series 
  
The benchmark chart above shows the percentage of patients 
reporting moderate or worse stress at referral who make a clinically 
significant improvement at episode end. 
Enterprise One: n = 20 (50.0%) 
All services: n = 1433 (59.2%) 
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Pain catastrophising  
Pain catastrophising is measured using the Pain Catastrophising Scale. Average subscale and total scores at 
referral and episode end are shown in Table 39. The proportion of people in each severity category at referral 
and episode end is shown in Figure 26. 
 
Table 39 – Pain 
catastrophising at referral 
and episode end 
Enterprise One 
n = 74 
All services 
n = 4851 
Referral score Episode end Referral score Episode end 
Total score 27.0 19.8 25.2 17.4 
- Rumination 8.8 6.5 8.5 5.9 
- Magnification 5.3 3.9 5.0 3.5 
- Helplessness 13.0 9.3 11.8 8.1 
 
Figure 26 – Pain catastrophising severity category at referral and episode end  
 
Figure 27 – Pain catastrophising benchmark results and time series 
  
The benchmark chart above shows the percentage of patients 
reporting moderate or worse pain catastrophising at referral who make 
a clinically significant improvement at episode end. 
Enterprise One: n = 29 (50.9%) 
All services: n = 1755 (57.0%) 
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Pain self-efficacy  
Pain self-efficacy is measured using the Pain Self-Efficacy Questionnaire. Average scores at referral and 
episode end are shown in Table 40. The proportion of people in each severity category at referral and episode 
end is shown in Figure 28.  
 
Table 40 – Self-efficacy at 
referral and episode end 
Enterprise One 
n = 76 
All services 
n = 4899 
Referral score Episode end Referral score Episode end 
Pain self-efficacy 24.7 30.2 23.0 31.9 
 
Figure 28 – Pain self-efficacy severity category at referral and episode end  
 
 
Figure 29 – Pain self-efficacy benchmark results and time series 
  
The benchmark chart above shows the percentage of patients 
reporting moderate or worse pain self-efficacy at referral who make a 
clinically significant improvement at episode end. 
Enterprise One: n = 27 (48.2%) 
All services: n = 1960 (53.3%) 
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Medication use 
The following information relates to the patients who completed an episode, and for whom medication 
information was recorded. Figure 30 shows the change in use of the main types of drugs from referral to 
episode end for these patients. 
 
Figure 30 – Medication use by drug type at referral and episode end 
 
 
For the patients who were taking opioid medication at referral, the average and median oMEDD at referral and 
at the end of the episode is shown in Table 41. Table 42 shows change in the frequency of use of opioid 
medications. 
 
Table 41 – oMEDD at 
referral and episode end 
Enterprise One 
n = 19 
All services 
n = 1436 
Referral Episode end Referral Episode end 
Average (mg) 51.8 60.0 46.5 31.1 
Median (mg) 30.0 40.0 30.0 12.0 
 
Table 42 – Frequency of 
use of opioid medication 
Enterprise One All services 
Referral  Episode end Referral  Episode end 
Using opioids >2 days per 
week 
48.8  41.9 47.5  35.1 
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Figure 31 – Opioid Use (all doses)  
  
The benchmark chart above shows the percentage of patients taking 
opioid medications at referral who reported a reduction in their 
oMEDD of at least 50% at episode end. 
Enterprise One: n = 3 (15.0%) 
All services: n = 734 (51.0%) 
 
 
Figure 32 – Opioid Use (high dose) 
  
The benchmark chart above shows the percentage of patients with an 
oMEDD of 40mg or more at referral who reported a reduction of at 
least 50% at episode end. 
Enterprise One: n = 0 (0.0%) 
All services: n = 272 (45.7%) 
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Work status and productivity 
The following information relates to the patients who completed an episode and reported work status and 
productivity information. Table 43 shows the work status for these patients at referral and episode end.  
 
Table 43 – Work status at referral 
and episode end 
Enterprise One 
n (%)   
All services 
n (%) 
Referral  Episode end Referral  Episode end 
Working full-time 11 (16.7) 8 (12.1) 1030 (24.0) 955 (22.3) 
Working part-time 8 (12.1) 9 (13.6) 726 (16.9) 734 (17.1) 
Unable to work due to pain  21 (31.8) 25 (37.9) 1657 (38.6) 1457 (34.0) 
Unable to work due to a condition 
other than pain 
14 (21.2) 11 (16.7) 390 (9.1) 438 (10.2) 
Not working by choice 12 (18.2) 11 (16.7) 410 (9.6) 485 (11.3) 
Seeking employment 0 (0.0) 2 (3.0) 76 (1.8) 220 (5.1) 
Total 66 (100.0) 66 (100.0) 4289 (100.0) 4289 (100.0) 
 
For the patients who reported that they were working full- or part-time at referral and episode end, additional 
information relating to work hours missed due to pain and lost productivity while at work was collected (Table 
44). 
 
Table 44 – Work productivity and 
impairment (%) for patients 
working full- or part-time 
Enterprise One All services 
Referral  Episode end Referral  Episode end 
Work time missed due to pain 25.6   2.6 36.4  23.7 
Pain affected work productivity 54.0  35.0 56.9  40.8 
Overall work impairment 68.4  36.8 65.0  46.4 
 
 
Health service utilisation 
Table 45 reports the average number of times patients used each health service type in the last three months 
for pain-related reasons.  
 
Table 45 – Pain-related health service 
use in the past 3 months, reported at 
referral and episode end  
Enterprise One All services 
Referral  
Episode 
end 
Referral  
Episode 
end 
General practitioner 3.0 2.8 3.7 2.5 
Medical specialist 1.0 0.8 1.5 0.9 
Other health professionals 4.8 4.1 6.4 5.8 
Emergency department presentations 0.3 0.3 0.4 0.2 
Hospital admissions 0.1 0.2 0.2 0.1 
Diagnostic tests 1.2 0.8 1.2 0.7 
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Patient outcomes at post-episode follow-up 
During the period 1 July 2019 to 30 June 2020, 61 of your patients completed a post-episode follow-up 
ePPOC questionnaire three to six months after the end of their episode of care.  
 
Global rating of change 
The global rating of change (GRC) captures the person’s perception about how their condition has changed 
(both overall and in respect to physical functioning) compared to before receiving treatment at the pain 
service.  
 
Figure 33 – Global rating of change at post-episode follow-up 
  
 
78.3% of your patients reported making at least some overall improvement4, and 73.3% reported an 
improvement in their physical abilities (63.2% and 60.9% for all services – see Figure 33). 
 
The following information in this section reports change from referral to episode end and post-episode 
follow-up for the patients who completed questionnaires at all three time points. 
 
 
 
 
 
 
 
 
 
                                                     
4 The sum of responses 1, 2, and 3. 
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Pain  
Pain severity  
Pain severity is measured using the Brief Pain Inventory (BPI). Average scores on the BPI at referral, episode 
end and post-episode follow-up are shown in Table 46. The proportion of people in each severity category at 
each time point is shown in Figure 34.  
 
Table 46 – Pain severity at 
referral, episode end and post-
episode follow-up 
Enterprise One 
n = 48 
All services 
n = 2113 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Pain severity 5.5 4.5 4.4 5.8 4.7 4.7 
- Worst pain 7.6 6.5 6.3 7.7 6.5 6.4 
- Least pain 3.9 2.9 2.9 4.0 3.2 3.2 
- Average pain 5.3 4.3 4.3 5.8 4.7 4.6 
- Pain now 5.1 4.3 4.0 5.7 4.6 4.5 
 
 
Figure 34 – Average pain category at referral, episode end and post-episode follow-up 
 
 
 
 
Table 47 – Proportion of patients making clinically 
significant improvement in average pain 
Episode end Post-episode 
Enterprise One 9 (26.5%) 8 (23.5%) 
All services 572 (33.7%) 575 (33.8%) 
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Pain interference 
The interference of pain in activities is measured using the Brief Pain Inventory (BPI). Average scores on the BPI 
at referral, episode end and post-episode follow-up are shown in Table 48. The proportion of people in each 
severity category at each time point is shown in Figure 35.  
 
Table 48 – Pain interference at 
referral, episode end and post-
episode follow-up 
Enterprise One 
n = 50 
All services 
n = 2202 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Pain interference 6.6 4.5 4.4 6.7 4.8 4.8 
 
 
Figure 35 – Pain interference severity category at referral, episode end and post-episode follow-up 
 
 
 
 
Table 49 – Proportion of patients making clinically 
significant improvement in pain interference 
Episode end Post-episode 
Enterprise One 30 (68.2%) 32 (72.7%) 
All services 1241 (65.5%) 1215 (64.1%) 
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Pain frequency 
Table 50 and Figure 36 report the percent of patients reporting the frequency at which pain is experienced at 
referral, end of the episode and post-episode follow-up. 
 
Table 50 – Pain frequency at referral, 
episode end and post-episode follow-up 
Enterprise One 
n = 49 
All services 
n = 2112 
Referral  
Episode 
end 
Post-
episode 
Referral  
Episode 
end 
Post-
episode 
Always present (same intensity) 4.1 8.2 6.1 9.8 6.0      6.1 
Always present (varying intensity) 79.6 51.0 55.1 73.8 56.0     52.9 
Often present 12.2 24.5 14.3 11.6 16.5     15.7 
Occasionally present 0.0 14.3 16.3 3.6 12.5     12.3 
Rarely present 4.1 2.0 8.2 1.2 7.9     11.2 
Pain no longer present 0.0 0.0 0.0 0.0 1.1      1.8 
Total 100.0 100.0 100.0 100.0 100.0 100.0 
 
 
Figure 36 – Pain frequency at referral, episode end and post-episode follow-up 
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Depression 
Depression is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average depression scores 
at referral, episode end and post-episode follow-up are shown in Table 51. The proportion of people in each 
severity category at each time point is shown in Figure 37.  
 
Table 51 – Depression at 
referral, episode end and post-
episode follow-up 
Enterprise One 
n = 49 
All services 
n = 2160 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Depression 20.3 13.3 13.6 17.5 12.2 12.5 
 
 
Figure 37 – Depression severity category at referral, episode end and post-episode follow-up 
 
 
 
 
 
Table 52 – Proportion of patients making clinically 
significant improvement in depression 
Episode end Post-episode 
Enterprise One 18 (52.9%) 19 (55.9%) 
All services 776 (62.5%) 711 (57.3%) 
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Anxiety 
Anxiety is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average anxiety scores at 
referral, episode end and post-episode follow-up are shown in Table 53. The proportion of people in each 
severity category at each time point is shown in Figure 38.  
 
Table 53 – Anxiety at referral, 
episode end and post-episode 
follow-up 
Enterprise One 
n = 48 
All services 
n = 2149 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Anxiety 12.9 9.5 10.9 11.7 9.4 9.6 
 
 
Figure 38 – Anxiety severity category at referral, episode end and post-episode follow-up 
 
 
 
 
Table 54 – Proportion of patients making clinically 
significant improvement in anxiety 
Episode end Post-episode 
Enterprise One 14 (48.3%) 16 (55.2%) 
All services 534 (48.2%) 537 (48.5%) 
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Stress 
Stress is measured using the Depression, Anxiety and Stress Scale (DASS 21). Average stress scores at referral, 
episode end and post-episode follow-up are shown in Table 55. The proportion of people in each severity 
category at each time point is shown in Figure 39.  
 
Table 55 – Stress at referral, 
episode end and post-episode 
follow-up 
Enterprise One 
n = 50 
All services 
n = 2145 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Stress 20.3 15.7 15.1 19.5 15.1 14.8 
 
 
Figure 39 – Stress severity category at referral, episode end and post-episode follow-up 
 
 
 
 
Table 56 – Proportion of patients making clinically 
significant improvement in stress 
Episode end Post-episode 
Enterprise One 17 (58.6%) 18 (62.1%) 
All services 682 (62.6%) 659 (60.5%) 
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Pain catastrophising  
Pain catastrophising is measured using the Pain Catastrophising Scale. Average subscale and total scores at 
referral, episode end and post-episode follow-up are shown in Table 57. The proportion of people in each 
severity category at each time point is shown in Figure 40.  
 
Table 57 – Pain catastrophising 
at referral, episode end and 
post-episode follow-up 
Enterprise One 
n = 47 
All services 
n = 2133 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Total score 25.4 15.0 14.1 25.5 16.9 16.5 
- Rumination 8.4 4.8 4.4 8.6 5.7 5.5 
- Magnification 5.5 3.0 3.0 5.1 3.4 3.4 
- Helplessness 11.5 7.0 6.5 11.9 7.8 7.6 
 
 
Figure 40 – Pain catastrophising severity category at referral, episode end and post-episode follow-up 
 
 
 
Table 58 – Proportion of patients making clinically 
significant improvement in pain catastrophising 
Episode end Post-episode 
Enterprise One 23 (69.7%) 23 (69.7%) 
All services 803 (58.9%) 835 (61.3%) 
 
 
 
  
P
o
st-e
p
iso
d
e
 o
u
tco
m
e
s 
 
Page 38 
Pain self-efficacy  
Pain self-efficacy is measured using the Pain Self-Efficacy Questionnaire. Average scores at referral, episode 
end and post-episode follow-up are shown in Table 59. The proportion of people in each severity category at 
each time point is shown in Figure 41. 
 
Table 59 – Pain self-efficacy at 
referral, episode end and post-
episode follow-up 
Enterprise One 
n = 50 
All services 
n = 2166 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-
episode 
Pain self-efficacy 24.4 34.1 34.5 23.1 32.8 32.7 
 
 
 
Figure 41 – Pain self-efficacy severity category at referral, episode end and post-episode follow-up 
 
 
 
Table 60 – Proportion of patients making clinically 
significant improvement in pain self-efficacy 
Episode end Post-episode 
Enterprise One 19 (54.3%) 23 (65.7%) 
All services 921 (57.1%) 853 (52.9%) 
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Medication use 
Of the patients who completed a referral, episode end and post-episode follow-up questionnaire at your 
service and for whom medication information has been recorded, Figure 42 shows the change in use of the 
main types of drugs at these time points. 
 
Figure 42 – Medication use by drug type at referral, episode end and post-episode follow-up 
 
 
For the patients who were taking opioid medication at referral, the average and median oMEDD at referral, 
episode end and at post-episode follow-up is shown Table 61. Table 62 shows change in the frequency of use 
of opioid medications. 
 
Table 61 – oMEDD at 
referral, episode end and 
post-episode follow-up  
Enterprise One 
n = 6 
All services 
n = 590 
Referral 
Episode 
end 
Post-
episode 
Referral 
Episode 
end 
Post-episode 
Average (mg) 18.5 9.0 21.0 47.4 33.1 33.5 
Median (mg) 7.1 2.0 0.5 30.0 15.0 10.0 
 
Table 62 – Frequency of use 
of opioid medication 
Enterprise One All services 
Referral  
Episode 
end 
Post-
episode 
Referral  
Episode 
end 
Post-
episode 
Percent using opioids >2 days 
per week 
35.0 18.0 18.0 49.0 36.0 36.0 
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Work status and productivity 
The following information relates to patients who completed work status and productivity questions at 
referral, episode end and post-episode follow-up. Table 63 shows work status at the three time points, and for 
the patients who were working, Table 64 shows information relating to work time missed due to pain and 
productivity. 
 
Table 63 – Work status at referral, 
episode end and follow-up (%) 
Enterprise One 
n = 27 
All services 
n = 1770  
Referral  
Episode 
end 
 Post-
episode 
Referral  
Episode 
end 
Post-
episode 
Working full-time 14.8 11.1 7.4 24.4 23.7 23.8 
Working part-time 3.7 18.5 18.5 15.5 16.2 15.3 
Unable to work due to pain  48.1 40.7 33.3 38.8 32.7 31.9 
Unable to work due to a condition other 
than pain 
11.1 11.1 7.4 8.8 9.8 9.8 
Not working by choice 18.5 18.5 25.9 10.1 12.6 12.1 
Seeking employment 3.7 0.0 7.4 2.6 5.1 7.1 
Total 100.0 100.0 100.0 100.0 100.0 100.0 
 
 
Table 64 – Work productivity and 
impairment (%) for patients 
working full- or part-time 
Enterprise One All services 
Referral  
Episode 
end 
 Post-
episode 
Referral  
Episode 
end 
Post-
episode 
Work time missed due to pain 60.0   0.0  21.1 32.9  20.6  16.0 
Pain affected work productivity 50.0  26.7  43.3 55.8  38.7  35.7 
Overall work impairment 72.0  25.0  52.5 63.2  43.6  39.0 
 
Health service utilisation 
Table 65 reports the average number of times patients used each health service type in the last three months 
for pain-related reasons.  
 
Table 65 – Pain-related health 
service use in the past 3 months, 
reported at referral, episode end 
and follow-up 
Enterprise One All services 
Referral  
Episode 
end 
 Post-
episode 
Referral  
Episode 
end 
Post-
episode 
General practitioner 3.3 2.0 2.1 3.7 2.5 2.2 
Medical specialist 1.2 0.4 0.6 1.4 0.9 0.7 
Other health professionals 4.3 3.3 2.9 6.6 5.9 3.4 
Emergency department presentations 0.4 0.3 0.4 0.3 0.2 0.1 
Hospital admissions 0.2 0.1 0.2 0.1 0.1 0.1 
Diagnostic tests 1.4 0.7 0.6 1.2 0.6 0.5 
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Appendix A – Additional patient outcomes  
Change from referral to first pathway start 
Table 66 reports scores on the assessment tools at referral and the start of the first treatment pathway. This 
information may be used to assess the effectiveness of interventions delivered prior to treatment pathways 
(e.g. education/orientation programs).  
Table 66 – Scores at referral and 
pathway start 
Enterprise One All services 
Referral  Pathway start Referral  Pathway start 
Pain severity 6.6 6.6 6.2 5.8 
Pain interference 7.6 7.4 7.0 6.4 
Depression 23.3 22.9 19.4 16.9 
Anxiety  16.6 17.7 13.1 12.5 
Stress 23.0 22.2 20.3 18.6 
Pain catastrophising 31.7 29.6 28.2 24.0 
Pain self-efficacy 18.0 19.8 21.8 24.9 
 
Change from pathway start to pathway end  
Measuring change from the beginning to the end of a treatment pathway allows pain services to compare 
change by pathway type. Services may use this information when reviewing the types of treatments they 
provide, for example, to determine the relative effectiveness of treatment pathways. 
88 patients completed a questionnaire at the end of their treatment pathway at your service during the period 
1 July 2019 to 30 June 2020, (all services, n = 5990). This section reports change from pathway start to 
pathway end for these patients. 
Global rating of change 
Figure 43 – Global rating of change at pathway end 
  
45.5% of your patients reported making at least some improvement overall5, and 38.2% reported an 
improvement in their physical abilities (71.1% and 68.2% at all services – See Figure 43). 
                                                     
5 The sum of 1, 2 and 3. 
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Pain severity  
Table 67 – Pain severity at 
pathway start and end 
Enterprise One 
n = 79 
All services 
n = 5248 
Pathway start Pathway end Pathway start Pathway end 
Pain severity score 5.7 4.9 5.8 4.9 
- Worst pain 7.6 6.7 7.7 6.6 
- Least pain 4.0 3.4 4.0 3.3 
- Average pain 5.7 5.0 5.7 4.8 
- Pain now 5.6 4.7 5.6 4.7 
 
    
Patients reporting clinically 
significant improvement, n (%) 
11 (18.0%) 1174 (28.6%) 
 
Figure 44 – Average pain at pathway start and end 
 
Pain interference 
Table 68 – Pain interference at 
pathway start and end 
Enterprise One 
n = 79 
All services 
n = 5401 
Pathway start Pathway end Pathway start Pathway end 
Pain interference score 6.4 5.2 6.5 5.1 
 
    
Patients reporting clinically 
significant improvement, n (%) 
41 (61.2%) 2631 (57.7%) 
 
Figure 45 – Pain interference at pathway start and end 
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Pain frequency 
Table 69 – Pain frequency at 
pathway start and pathway end 
Enterprise One 
n =80  
All services 
n = 5218 
Pathway start Pathway end Pathway start Pathway end 
Always present (same intensity) 15.0 11.3 9.4 6.8 
Always present (varying intensity) 71.3 61.3 72.6 56.9 
Often present 10.0 15.0 12.6 15.9 
Occasionally present 1.3 10.0 3.9 11.9 
Rarely present 2.5 2.5 1.5 7.4 
Pain no longer present 0.0 0.0 0.0 1.0 
Total 100.0 100.0 100.0 100.0 
 
Figure 46 – Pain frequency – distribution at pathway start and pathway end 
 
Depression 
Table 70 – Depression at 
pathway start and end 
Enterprise One 
n = 78 
All services 
n = 5325 
Pathway start Pathway end Pathway start Pathway end 
Depression score 18.2 13.1 17.1 12.9 
 
    
Patients reporting clinically 
significant improvement, n (%) 
26 (57.8%) 1618 (54.2%) 
 
Figure 47 – Depression at pathway start and end 
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Anxiety 
Table 71 – Anxiety at pathway 
start and end 
Enterprise One 
n = 77 
All services 
n = 5316 
Pathway start Pathway end Pathway start Pathway end 
Anxiety score 13.6 10.8 11.8 9.9 
 
    
Patients reporting clinically 
significant improvement, n (%) 
18 (35.3%) 1148 (41.9%) 
 
Figure 48 – Anxiety at pathway start and end 
 
 
Stress 
Table 72 – Stress at pathway 
start and end 
Enterprise One 
n = 79 
All services 
n = 5311 
Pathway start Pathway end Pathway start Pathway end 
Stress score 19.3 15.7 19.3 15.6 
 
    
Patients reporting clinically 
significant improvement, n (%) 
19 (50.0%) 1451 (56.0%) 
 
Figure 49 – Stress at pathway start and end 
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Pain catastrophising 
Table 73 – Pain catastrophising 
at pathway start and end 
Enterprise One 
n = 76 
All services 
n = 5280 
Pathway start Pathway end Pathway start Pathway end 
Pain catastrophising score 25.1 18.6 24.5 17.9 
- Rumination 8.2 6.1 8.2 6.0 
- Magnification 5.0 3.8 4.9 3.6 
- Helplessness 12.0 8.8 11.4 8.3 
 
    
Patients reporting clinically 
significant improvement, n (%) 
25 (49.0%) 1701 (52.5%) 
 
Figure 50 – Pain catastrophising at pathway start and end 
 
Pain self-efficacy 
Table 74 – Pain self-efficacy at 
pathway start and end 
Enterprise One 
n = 79 
All services 
n = 5329 
Pathway start Pathway end Pathway start Pathway end 
Pain self-efficacy score 25.6 29.8 23.5 31.2 
 
    
Patients reporting clinically 
significant improvement, n (%) 
19 (40.4%) 1894 (48.4%) 
 
Figure 51 – Pain self-efficacy at pathway start and end 
 
 
A
p
p
e
n
d
ice
s 
Episode Information 
 
Page 46 
Outcomes by treatment pathway(s)  
The tables below show average scores on the assessment tools at pathway start and pathway end by the 
treatment pathway(s) type, for your service (Table 75) and all services (Table 76).  
 
Table 75 – Scores at 
pathway start and end 
by pathway type(s) – 
Enterprise One 
Enterprise One 
Group program 
Individual 
appointments 
Concurrent (group 
and individual) 
Other 
n=10 n=15 n=55 n=0 
Start End Start End Start End Start End 
Pain severity 6.7 6.3 6.3 5.4 5.4 4.5 - - 
Pain interference 7.1 6.7 6.2 5.1 6.3 4.9 - - 
Depression 25.4 22.8 16.0 10.5 17.6 11.8 - - 
Anxiety 18.6 16.6 12.1 9.3 13.1 9.9 - - 
Stress 22.6 19.6 17.9 16.2 19.0 14.8 - - 
Pain Catastrophising  31.0 30.3 21.6 17.9 24.7 17.0 - - 
Pain Self-Efficacy  26.2 21.8 28.6 34.6 24.8 30.3 - - 
 
 
Table 76 – Scores at 
pathway start and end 
by pathway type(s) - 
All services 
All services 
Group program 
Individual 
appointments 
Concurrent (group 
and individual) 
Other 
n=1421 n=3359 n=618 n=72 
Start End Start End Start End Start End 
Pain severity 5.8 5.3 5.7 4.6 6.0 5.1 6.1 4.5 
Pain interference 6.6 5.5 6.5 4.9 7.0 5.3 5.9 4.7 
Depression 18.8 14.8 15.6 11.7 21.4 15.4 15.5 11.6 
Anxiety 13.3 11.3 10.7 9.0 14.8 12.4 9.3 8.6 
Stress 20.3 17.1 18.3 14.6 22.5 17.9 16.9 14.0 
Pain Catastrophising  25.5 19.9 23.3 16.6 28.9 21.0 23.6 19.6 
Pain Self-Efficacy  23.2 30.0 24.2 32.0 20.2 28.8 27.1 32.9 
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Outcomes by group program hours 
The tables below show average scores on the assessment tools at pathway start and pathway end by group 
program intensity, for your service (Table 77) and all services (Table 78).  
 
 
Table 77 – Scores at 
pathway start and end by 
group program hours – 
Enterprise One 
Enterprise One 
6 to < 24 hours 24 to <60 hours 60+ hours 
n=18 n=0 n=0 
Start End Start End Start End 
Pain severity 6.0 5.2 - - - - 
Pain interference 6.3 5.2 - - - - 
Depression 19.8 15.6 - - - - 
Anxiety 15.5 12.7 - - - - 
Stress 20.8 16.0 - - - - 
Pain Catastrophising  27.9 23.2 - - - - 
Pain Self-Efficacy  28.2 29.9 - - - - 
 
 
Table 78 – Scores at 
pathway start and end by 
group program hours – 
All services 
All services 
6 to < 24 hours 24 to <60 hours 60+ hours 
n=392 n=348 n=621 
Start End Start End Start End 
Pain severity 5.8 5.2 5.5 4.8 6.2 5.3 
Pain interference 6.4 5.4 6.4 5.0 7.1 5.4 
Depression 17.5 14.3 16.8 12.7 22.9 16.4 
Anxiety 13.0 10.6 11.6 9.8 15.5 12.8 
Stress 18.6 15.8 19.3 15.7 23.7 18.8 
Pain Catastrophising  24.1 19.0 24.4 17.3 30.0 22.3 
Pain Self-Efficacy  24.9 30.9 25.4 32.5 18.8 27.8 
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Appendix B – Data quality and completeness 
This section provides information about the number and type of questionnaires returned, questionnaire 
response rates and individual item completion. Response rate refers to the number of questionnaires returned 
as a percent of the number sent. 
 
 
Table 79 – Number of 
questionnaires completed and 
response rate by questionnaire type 
Enterprise One All Services 
Response rate Response rate 
Referral 80.0 78.0 
Pathway start 87.0 74.0 
Group program start  
(concurrent pathways only) 
97.0 86.0 
Pathway review 67.0 59.0 
Group program end  
(concurrent pathways only) 
89.0 81.0 
Pathway end 95.0 70.0 
Post episode  83.0 47.0 
Ad hoc 70.0 65.0 
 
 
 
 
 
 
Table 80 – Item completion  
(percent complete) 
Enterprise One All Services 
Indigenous status 86.3 95.9 
Country of birth 97.4 98.6 
Interpreter required 98.3 98.3 
Communication assistance 95.1 95.1 
Main pain site 73.8 83.5 
How main pain began 96.1 97.3 
Pain duration 96.5 96.8 
Health service use   
- General practitioner 91.9 94.8 
- Medical specialist 86.8 91.8 
- Other health professionals 87.4 91.6 
- Hospital emergency department 84.4 90.2 
- Admitted to hospital 83.8 90.0 
- Diagnostic tests 86.7 92.0 
Pain frequency 98.2 96.2 
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Table 81 – Assessment tool 
validity and completion 
Validity – 
number of 
items that 
must be 
completed 
Enterprise One All Services 
Average 
number of 
completed 
items 
% of validly 
completed 
questionnaires 
Average 
number of 
completed 
items 
% of validly 
completed 
questionnaires 
Brief Pain Inventory      
- Worst pain 1/1 -     98.0 -     98.4 
- Least pain 1/1 -     97.1 -     97.9 
- Average pain 1/1 -     97.5 -     97.9 
- Pain now 1/1 -     98.0 -     98.0 
Pain severity 4/4 3.9     95.9 3.9     96.8 
Pain interference 4/7 6.8     98.5 6.9     98.7 
Depression, Anxiety, Stress Scale      
- Depression 6/7 6.8     96.7 6.8     97.0 
- Anxiety 6/7 6.8     96.7 6.8     96.8 
- Stress 6/7 6.8     96.9 6.8     96.8 
Pain Catastrophising Scale       
- Rumination 4/4 3.8     94.9 3.9     95.6 
- Magnification 3/3 2.9     94.9 2.9     95.4 
- Helplessness 6/6 5.8     93.2 5.8     94.5 
- Total 12/13 12.5     94.9 12.6     96.2 
Pain Self-Efficacy Questionnaire 9/10 9.7     96.9 9.8     97.8 
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Appendix C – Tips for interpreting the report 
 
How information is presented in this report 
In this report we have attempted to report information in a way that puts the patient at the centre of care and 
provides a sense of flow that mirrors the patient journey. 
Information describing the people attending pain services is found in the Patient Profile section and includes 
socio-demographic details and clinical characteristics at referral. A description of typical episodes of care, 
including wait time, length and services provided are shown in the Episode Details section. Outcomes for the 
patient, at both the end of the episode and 3-6 months after the episode has ended are shown in the Episode 
Outcomes and Post-episode Outcomes sections, respectively. 
 
The benchmarks 
There are nine ePPOC clinical benchmarks and two wait time indicators. The benchmarks show the percent of 
patients experiencing a clinically significant improvement or meeting predetermined conditions (see Appendix 
E – Assessment tools for more details). This report also includes time series graphs, which show change in 
performance on each of the benchmarks at 12 month intervals over a five year period for either Mid-Year or 
Annual reports. 
 
Interpreting the graphs 
Benchmarks and Indicators 
 
 The vertical axis shows the % of 
patients experiencing a clinically 
significant improvement 
 The red line indicates the current 
benchmark level 
 The light blue region shows the 
Australasian profile for this 
benchmark. It contains all services 
that contributed to this benchmark, 
ordered from the highest to the 
lowest level of achievement 
 The blue triangle highlights your 
services score relative to the 
benchmark and other contributing 
services. If there is no triangle on 
your graph this indicates that your 
service reported less than 10 
outcomes for this benchmark 
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Time series 
 
 Results are reported at 12 month intervals over a 5 year 
period with either Mid Year (MY) or Annual results, 
corresponding to the current report 
 
 Results are based on the current benchmark/ indicator 
definition and may not precisely match previously reported 
results due to a change in definition and/or updated data 
 
 The darker line indicates the result for your service 
 
 The lighter line indicates the average for All  services 
 
 The red line indicates the threshold at which the 
benchmark/indicator is currently set 
 
 If there is no dot for your service for any period, this 
indicates that your service reported less than 10 outcomes 
for this benchmark during that period. 
 
Socioeconomic disadvantage 
These charts show the relative socioeconomic disadvantage of your patient population based on residential 
address at referral. The information uses the Socio-Economic Index for Areas – Index of Relative Disadvantage, 
and the New Zealand Index of Relative Socioeconomic Deprivation. These indices group residential area into 
five disadvantage quintiles (from least to most disadvantage) such that across the national Australian and New 
Zealand populations, 20% of people live in each disadvantage quintile. It’s important to note that the level of 
disadvantage relates to the area the person lives in rather than the person.  
The chart compares the proportion of your patients who live in each disadvantage quintile to the:  
 population of all people seeking pain management in Australasia (All services)  
 expected distribution of disadvantage (Australasian expected %)  
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Appendix D – Pain services that submitted data for this 
report (‘All services’)  
 
New South Wales: Central Coast Integrated Pain Service, Gosford Hospital, Concord Repatriation General 
Hospital (Multidisciplinary Pain Clinic), Greenwich Hospital Pain Management Services, Innervate Pain 
Management, Hunter Integrated Pain Service, John Hunter Hospital, Lismore Base Hospital - Pain Clinic, 
Liverpool Hospital Chronic Pain Services, Coffs Harbour Chronic Pain Service, Nepean Pain Unit, Orange 
Chronic Pain Clinic, Illawarra Shoalhaven Chronic Pain Service, Prince of Wales Hospital, Department of Pain 
Management, Michael J Cousins Pain Management and Research Centre Royal North Shore Hospital, Royal 
Prince Alfred PMC, St George Hospital Pain Management Unit, St Vincent's Hospital Sydney Pain Clinic, Sydney 
Spine and Pain Rehab Pty Ltd, Tamworth Integrated Pain Service (TIPS), Westmead Hospital 
 
Queensland: Interventus Pain Specialists, Metro South Health Persistent Pain Management Service (Princess 
Alexandra Hospital), Sunshine Coast Persistent Pain Management Service, St Vincent's Private Hospital Ltd T/as 
St Vincent's Private Hospital Brisbane, Tess Cramond Pain and Research Centre, North Queensland Persistent 
Pain Management Service, QLD Health (Townsville Hospital), Wesley Hospital, Brisbane (UnitingCare Health - 
UCH)  
 
South Australia: Flinders Pain Management Unit, Northern Pain Rehabilitation Service (Modbury Hospital), 
Central Adelaide Local Health Network (CALHN) Queen Elizabeth Hospital 
  
Victoria: Advance Healthcare, Austin Pain Service, Austin Health, Bendigo Health (Outpatient Rehabilitation 
Services, Pain Rehabilitation Clinic), Caulfield Pain Management and Research Centre, Caulfield Hospital (Alfred 
Health), Dorset Rehabilitation Centre, Eastern Health Ambulatory Pain Management Service, Empower Rehab, 
Epworth Hospital (Epworth Healthcare), Goulburn Valley Health Chronic Pain Clinic, Latrobe Regional Hospital, 
Melbourne Health, Monash Health, Northern Health Service, Peninsula Health Integrated Pain Service 
(Persistent Pain Management Service), Precision Ascend, Royal Women's Hospital, Barbara Walker Centre for 
Pain Management (St Vincent's Hospital, Melbourne), Victorian Rehabilitation Centre, The, Western Health 
Pain Management 
 
Western Australia: Fiona Stanley Hospital Pain Management Unit, Pelvic Pain Clinic, King Edward Memorial 
Hospital, Subiaco WA, PainCare, Sir Charles Gairdner Hospital,  
 
New Zealand: Active+ Ltd, Advantage South,  The Auckland Regional Pain Service DHB (TARPS, Auckland 
Regional Hospital), APM NZ, Body in Motion, Canterbury DHB (Burwood Hospital Pain Management Centre), 
Capital and Coast DHB (Wellington Hospital), Futureproof Rehab Ltd, Habit Rehabilitation Ltd, Hutt Valley 
District Health Board, Integrative Pain Care Ltd, Nelson Nursing Services, Pain Management & Rehabilitation 
Services, Pain Rehabilitation Christchurch Ltd, Proactive Rehab, Occupational Health Canterbury, Southern 
Rehab, Proactive Southern Limited, QE Health Limited, Taranaki DHB Persistent Pain Service, TBI Health Group 
Ltd 
 
A list of all services participating in ePPOC can be found on the ePPOC web site: 
https://ahsri.uow.edu.au/eppoc  
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Appendix E – Assessment tools 
The assessment tools used in ePPOC are: 
 Brief Pain Inventory (BPI) 
 Depression, Anxiety, Stress Scale (DASS) 
 Pain Catastrophising Scale (PCS) 
 Pain Self-Efficacy Questionnaire (PSEQ) 
 Global Rating of Change (GRC) 
 Work Productivity and Impairment (WPAI) 
 CARRA Body Chart. 
Each of these assessment tools are briefly described below. 
Brief Pain Inventory6 
The BPI items used in the ePPOC dataset measure the severity of pain and the degree to which the pain 
interferes with common activities of daily living. Pain severity questions are rated on a scale of 0 to 10,  
where 0 = ‘No pain’ and 10 = ‘Pain as bad as you can imagine’, with patients asked to rate their pain in four 
items including, average, worst and least pain over the last week, and their pain right now. Pain severity is then 
calculated as an average of these four items. Whereas the benchmark for average pain is based on the single 
average pain item only.  
Severity bands for these items are: 
 0-4 = mild pain 
 5-6 = moderate pain 
 7-10 = severe pain 
The IMMPACT group’s recommendations for assessing clinical significance for 0-10 numeric pain scales are 
that a change of:  
≥ 10% represents minimally important change 
≥ 30% represents moderate clinically important change (ePPOC uses this category to identify clinically 
significant improvement for average and worst pain) 
≥ 50% represents substantial clinically important change. 
The interference questions are rated on a scale of 0 to 10, where 0 = ‘Does not interfere’ and  
10 = ‘Completely interferes’. The interference subscale is an average of the seven interference questions.  
At least 4 of 7 questions must be completed for this subscale to be valid. The IMMPACT recommendation for 
assessment of clinically significant change on the BPI interference scale is a change of 1 point over the average 
of the 7 items7. 
  
                                                     
6 Modified Brief Pain Inventory, reproduced with acknowledgement of the Pain Research Group, University of Texas, MD 
Anderson Cancer Centre, USA 
7 Dworkin, RH, et al 2008, ‘Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: 
IMMPACT Recommendations.’ The Journal of Pain, vol. 9, no. 2, pp 105-121. 
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Depression Anxiety Stress Scales8 
The DASS measures the negative emotional states of depression, anxiety and stress. Due to the large number 
of questions in the full DASS (42 questions), the DASS21 is administered. This comprises 21 questions which 
are rated on a scale of 0 to 3, where 0 = ‘did not apply to me at all’, 1 = ‘applied to me to some degree, or 
some of the time’, 2 = ‘applied to me to a considerable degree, or a good part of the time’, or 3 = ‘applied to 
me very much, or most of the time’. Scores are multiplied by 2 to enable comparison with the full-scale 
DASS42 for which norms exist. 
For each subscale (Depression, Anxiety and Stress), the 7 items are summed and then multiplied by 2. The test 
developers suggest that at least 6 of 7 items should be complete for each subscale to be considered valid. 
Table 55 shows the range of scores associated with severity categories for each subscale. 
 
Table 82 – DASS severity ratings Depression Anxiety Stress 
Normal 0-9 0-7 0-14 
Mild 10-13 8-9 15-18 
Moderate 14-20 10-14 19-25 
Severe 21-27 15-19 26-33 
Extremely Severe 28+ 20+ 34+ 
 
Clinical significance on each of the DASS subscales requires a change of 5 or more points coupled with a move 
to a different severity category.  
Pain Catastrophising Scale9 
The PCS measures a patient’s thoughts and feelings related to their pain. This includes three subscales 
measuring the dimensions of Rumination, Magnification and Helplessness. The PCS comprises 13 questions 
(Rumination – 4 items, Magnification – 3 items, Helplessness – 6 items) which are rated on a scale of 0 to 4, 
where 0 = ‘not at all’, 1 = ‘to a slight degree’, 2 = ‘to a moderate degree’, 3 = ‘to a great degree’ and  
4 = ‘all the time’. For each subscale, all items must be completed to be valid. For the total to be valid, at least 
12 of 13 items must be completed. 
Severity bands for the PCS are: 
 <20 = mild 
 20 to 30 = high 
 >30 = severe. 
Clinically significant change requires a change in score of 6 or more points, combined with movement to a 
different severity category10.  
  
                                                     
8 Lovibond, SH and Lovibond, PF 1995, Manual for the Depression Anxiety Stress Scales, Psychology Foundation 
Monograph, Sydney, Australia. 
9 Sullivan, MJL, et al 1995, ‘The Pain Catastrophizing Scale: Development and Validation’, Psychological Assessment, vol. 7, 
num. 4, pp 524-532. 
10 Sullivan, MJL, personal communication with Nicholas, MK July 2014. A
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Pain Self-Efficacy Questionnaire 
The PSEQ measures how confident a patient is that he or she can do a range of activities despite their pain. 
The PSEQ Total is a sum of scores from 10 questions which are rated on a scale from 0 = ‘Not confident at all’ 
to 6 = ‘Completely confident’. At least 9 of 10 items must be complete for the PSEQ Total to be valid. Increases 
in score represent an improvement in self-efficacy.  
Severity bands for the PSEQ are: 
 <20 = severe 
 20 to 30 = moderate 
 31 to 40 = mild 
 >40 = minimal impairment. 
Clinically significant change requires a change in score of 7 or more points, combined with movement to a 
different severity category11.  
Global Rating of Change12 
The Global Rating of Change questions were included in Version 2 of the ePPOC dataset. They are asked in 
follow-up questionnaires only. The two questions are “Compared with before receiving treatment at this pain 
management service, how would you describe yourself now overall?” and “Compared with before receiving 
treatment at this pain management service, how would you describe your physical abilities now?” Participants 
answer by indicating their response on a Likert scale from -3 (very much worse) to +3 (very much better). This 
will provide an overview of how participants perceive their condition has changed overall as well as with 
respect to their physical functioning.  
Work Productivity and Impairment (WPAI)13 
WPAI outcomes are expressed as impairment %s, with higher numbers indicating greater impairment and less 
productivity. The work status of all patients is collected using the International Consortium for Health 
Outcomes Measurement (ICHOM) categories. For patients who are employed,  
the WPAI items allow calculation of the following outcomes: 
 % of time missed from work due to pain (absenteeism) 
 % work impairment while working due to pain (lost productivity) 
 % overall work impairment due to pain (taking into account absenteeism and lost productivity). 
For more information on the calculations used please see the ePPOC Australian and New Zealand data 
dictionaries on the ePPOC website https://ahsri.uow.edu.au/eppoc/forms/index.html. 
 
  
                                                     
11 Nicholas, MK, personal communication, July 2014. 
12 Bartlett, A, Flett, P, Tardif, H and Hush, J 2017, Introducing a global measure of function and change in NSW pain services, 
37th ASM of the Australian Pain Society, Adelaide, Australia. 
13 Reilly MC, Zbrozek AS, Dukes E 1993, ‘The validity and reproducibility of a work productivity and activity impairment 
measure’, PharmacoEconomics, vol. 4, num. 5, pp 353-365. 
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CARRA Body Chart14 
Patients identify the site/s they feel pain using body maps. For reporting, pain sites are categorised into pain 
areas as follows: 
 
 
Table 83 – Pain area categories Pain sites 
Head head and face 
Neck neck 
Chest chest 
Back upper back, mid back and low back  
Leg left and right thighs, left and right calves, left and right ankles 
Arm/shoulder 
left and right shoulders, left and right upper arms, left and right elbows, left 
and right forearms, left and right wrists 
Abdomen abdomen 
Hands left and right hands 
Feet left and right feet 
Pelvic and/or genital pelvic/groin 
Knee left and right knees 
Hip left and right hips 
 
 
 
 
 
  
                                                     
14 Von Bayer CL, et al. 2011, ‘Pain charts (body maps or manikins) in assessment of location of paediatric pain’, Pain 
Management, vol. 1 num. 1, pp 61-68. (Source: Childhood Arthritis and Rheumatology Research Alliance, 
www.carragroup.org) A
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